ClinicalTrials.gg
RecruitingNCT04851015LOW-DOSEUpdated Feb 20, 2026

Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

A Phase 3 interventional study of trimethoprim-sulfamethoxazole and trimethoprim-sulfamethoxazole in Pneumocystis, Pneumocystis Pneumonia and Pneumocystis Jirovecii Infection, sponsored by Todd C. Lee MD MPH FIDSA. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Todd C. Lee MD MPH FIDSA · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Pneumocystis jirovecii pneumonia (PCP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX.

Reduced treatment doses of TMP-SMX for PCP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PCP for the primary outcome of Win Ratio hierarchical composite of death, ECMO, invasive ventilation, grade 4 toxicity, non-invasive ventilation, change of therapy and length of stay.

Read the detailed description

Pneumocystis jirovecii pneumonia (PCP) is an opportunistic fungal infection primarily affecting immunocompromised patients. Adults with HIV (particularly CD4 ≤200 cells/µL), solid organ and allogeneic hematopoietic stem cell transplant recipients, as well as patients on certain chemotherapies, immunosuppressant drugs, and systemic corticosteroids are at a highest risk. Although routine primary prophylaxis has diminished its prevalence, PCP still results in significant morbidity and mortality worldwide. Retrospective cohort studies have reported mortality rates between 20-50% among non-HIV populations and 10-20% for patients with HIV.

Current guidelines from the National Institutes of Health (NIH), the HIV Medicine Association of the Infectious Diseases Society of America (IDSA), and the American Society of Transplantation (AST) all recommend weight-based trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of the trimethoprim component as the standard of care. Yet, higher doses of TMP-SMX are associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure with adverse drug events (ADEs) reported among 20-60% of patients on treatment.

To better inform the optimal dosing strategy for PCP therapy, we recently performed a systematic review and meta-analysis of reduced dose regimens of TMP-SMX in the treatment of PCP among immunocompromised adult patients with and without HIV. When comparing standard doses to reduced doses (≤10mg/kg/day of the TMP component), there was no statistically significant difference in mortality (absolute risk difference: -9% in favor of reduced dose, 95% CI: -27% to 8%) with a corresponding 18% (95% CI: -31% to -5%) absolute risk reduction of Grade III or higher adverse events. These data provide the best available evidence for treatment equipoise and highlight the need for a randomized controlled trial to directly compare dosing strategies.

The primary objective of this trial is to determine whether treatment with reduced-dose TMP-SMX (10mg/kg/day) is superior to standard dose (15mg/kg/day) among immunocompromised HIV-infected and uninfected patients with PCP for the primary outcome of Win Ratio hierarchical composite of death, ECMO, invasive ventilation, grade 4 toxicity, non-invasive ventilation, change of therapy and length of stay, new mechanical ventilation, or change in treatment by Day 30.

02

Conditions studied

  • Pneumocystis
  • Pneumocystis Pneumonia
  • Pneumocystis Jirovecii Infection
  • Pneumocystis Infections
  • Pneumocystis Carinii Infection
  • Pneumocystosis; Pneumonia (Etiology)
  • Pneumocystis Carinii; Infection, Resulting From HIV Disease
  • Pneumocystosis Associated With AIDS

Keywords

  • Pneumocystis
  • PCP
  • PJP
  • immunosuppressed
  • HIV
  • TMP-SMX
03

In context

Pneumonia, Pneumocystis

108 studies on the registry are indexed under Pneumonia, Pneumocystis; 16 are open to participants now.

This study's planned enrollment of 416 is above the median of 231 across 56 interventional studies indexed under Pneumonia, Pneumocystis.

Browse Pneumonia, Pneumocystis studies →

Lead sponsor

Todd C. Lee MD MPH FIDSA is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • (including but not limited to , solid organ transplant, solid tumors, hematological stem cell transplant and , systemic diseases, chemotherapy, long term use, and immunosuppressive therapies, as well as primary immunodeficiencies
  • Presentation to a day hospital, emergency department, or admitted to hospital
  • Proven or probable diagnosis of PCP using an adapted version of the 2021 EORTC/MSGERC criteria.

Exclusion criteria

Exclusion Criteria:

  • Previous severe adverse reaction to TMP-SMX, any sulfa drug, or any component of formulation
  • Compliant with PCP prophylaxis for ≥4 weeks with TMP-SMX at enrollment
  • More than 96 hours of any therapy for PCP
  • Hepatic impairment marked by levels ≥5 times the
  • Known G6PD deficiency
  • Known diagnosis of porphyria
  • Known pregnancy or breastfeeding (as per Health Canada)
  • Unable to provide and no available healthcare proxy (with ethics approval for deferred consent in cases of critical illness); refusal of consent; no reliable means of outpatient contact (telephone/email/text);
  • Previously enrolled
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
416 participants (estimated)

Study arms

  • Experimental
    Reduced dose TMP-SMX

    Trimethoprim-Sulfamethoxazole at a total dose of 10mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as a dose of 10mg/kg/day open label with additional placebo tablets or intravenous placebo solution given to simulate 15mg/kg/day. All doses will be adjusted for obesity and renal function.

    Drug: trimethoprim-sulfamethoxazole

  • Active comparator
    Standard dose TMP-SMX

    Trimethoprim-Sulfamethoxazole at a total dose of 15mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as 10mg/kg/day open label plus an extra masked 5mg/kg/day of tablets or intravenous solution. All doses will be adjusted for obesity and renal function.

    Drug: trimethoprim-sulfamethoxazole

Interventions

  • Drugtrimethoprim-sulfamethoxazole

    10mg/kg/day of TMP component

    Also known as: Reduced dose

  • Drugtrimethoprim-sulfamethoxazole

    15mg/kg/day of TMP component

    Also known as: Standard dose

06

What researchers measure

Primary outcomes

  1. Hierarchical composite outcome

    Hierarchical composite of Win Ratio at day 30: * death; * new extracorporeal membrane oxygenation (ECMO), * new invasive mechanical ventilation; * severe (CTCAE grade 4) adverse drug event (dermatologic, nephrologic, hematologic, neurologic, and/or endocrinologic) considered at least probable (by Leape and Bates criteria); * new non-invasive ventilation; * change of therapy (i.e., dose or agent) due to presumed treatment failure or probable adverse drug reaction (by Leape and Bates criteria); and * length of stay in hospital (amongst survivors)

    Time frame: Day 30

Secondary outcomes

  1. Proportion of patients that die (death)

    All cause mortality

    Time frame: Day 30

  2. Proportion of patients with a need for new extracorporeal membrane oxygenation (ECMO)

    New initiation of extracorporeal membrane oxygenation during hospitalization following initiation of assigned PCP treatment strategy.

    Time frame: Day 30

  3. Proportion of patients requiring new Invasive Mechanical Ventilation

    Initiation of invasive mechanical ventilation via endotracheal intubation during hospitalization following initiation of the assigned PCP treatment strategy.

    Time frame: Day 30

  4. . Proportion of patients with severe (CTCAE grade 4) adverse drug event

    Proportion of patients with occurence of severe (CTCAE grade 4) adverse drug event (dermatologic, nephrologic, hematologic, neurologic, and/or endocrinologic) considered at least probable (by Leape and Bates criteria).

    Time frame: Day 30

  5. Proportion of patients with need for new non-invasive ventilation

    initiation of non-invasive ventilation (including continuous positive airway pressure \[CPAP\] or bilevel positive airway pressure \[BiPAP\] during hospitalization following initiation of the assigned PCP treatment strategy.

    Time frame: Day 30

  6. Proportion of patients requiring escalation or change of PCP -directed therapy

    Proportion of patients with escalation or change of PCP -directed therapy due to inadequate clinical response, disease progression, or treatment-limiting toxicity during the treatment or follow-up period.

    Time frame: Day 30

  7. Median length of stay in hospital amongst survivors

    Length of hospital stay, measured in days from hospital admission to discharge among participants who survive to hospital discharge.

    Time frame: Day 30

Other outcomes

  1. Tertiary outcome measure of quality of life at day 30

    Quality of life (EQ-5D-5L) wherein a higher score indicates better quality of life.

    Time frame: Day 30

  2. Tertiary outcome measure of all-cause mortality

    All-cause mortality, defined as death from any cause.

    Time frame: Day 180

  3. Tertiary Outcome Measure of PCP recurrence

    Recurrence of pneumocystis pneumonia, defined as a new episode of clinically and/or microbiologically confirmed PCP after initial resolution.

    Time frame: Day 180

  4. Tertiary Outcome measure of quality of life at day 180

    Quality of life assessed using a EQ-5D-5L questionnaire. High score indicates better quality of life.

    Time frame: Day 180

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng MP, McDonald EG, Lee TC. Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis. Open Forum Infect Dis. 2020 Apr 2;7(5):ofaa112. doi: 10.1093/ofid/ofaa112. eCollection 2020 May. PubMed 32391402 ↗
  • Sohani ZN, Butler-Laporte G, Aw A, Belga S, Benedetti A, Carignan A, Cheng MP, Coburn B, Costiniuk CT, Ezer N, Gregson D, Johnson A, Khwaja K, Lawandi A, Leung V, Lother S, MacFadden D, McGuinty M, Parkes L, Qureshi S, Roy V, Rush B, Schwartz I, So M, Somayaji R, Tan D, Trinh E, Lee TC, McDonald EG. Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial. BMJ Open. 2022 Jul 21;12(7):e053039. doi: 10.1136/bmjopen-2021-053039. PubMed 35863836 ↗

Individual participant data

Plan to share: Yes — A copy of a trial data required to replicate trial publication analyses will be shared within 3-6 months of publication. After study completion, a fully de-identified copy of the full trial dataset can be made available to other researchers subject to a data sharing agreement enacted under Quebec law.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: 3-6 months post publication

Access criteria: Trial data and analytic code required to replicate any analyses presented in the publication will be shared openly via a website which we will set up at that time. For a copy of the complete de-identified dataset, we will require a formal data sharing agreement (enacted under Quebec law) between the requesting group and the RI-MUHC.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Sep 2030, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2021
First posted
Apr 20, 2021
StartActual
Nov 28, 2025
Primary completionEst.
Sep 30, 2030
CompletionEst.
Dec 31, 2030
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04851015
Lead sponsor
Todd C. Lee MD MPH FIDSA
Responsible party
Todd C. Lee MD MPH FIDSA (Professor of Medicine, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Sponsor-investigator
First posted
Apr 20, 2021
Start date
Nov 28, 2025
Primary completion
Sep 30, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Feb 20, 2026

Study contacts

Babykumari Chitramuthu, PhD
Contact
babykumari.chitramuthu@muhc.mcgill.ca
514-934-1934 ext. 23730
Emily G McDonald, MD MSc
principal investigator · Research Institute of the McGill University Health Centre
Todd C Lee, MD MPH FIDSA
principal investigator · Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion